Technology | May 01, 2012

Theragenics Receives FDA Clearance for Galt VTI Valved Tearaway Introducer

New product in offers ergonomic, low-profile integrated valve

May 1, 2012 — Theragenics Corp. announced that Galt Medical, a wholly-owned subsidiary of Theragenics, has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Galt VTI valved tearaway introducer. Introducers are utilized for vascular access, with the Galt VTI expected to be utilized primarily for placing catheters.

The Galt VTI is a tearaway introducer that includes an ergonomic low-profile patent-pending integrated valve. The Galt VTI allows surgeons the ability to introduce or provide access for other medical devices to enter into a patient’s vascular system, reducing the risk of an air embolism and leakage. The Galt VTI is a less bulky and a more compact design than similar products currently available.

The addressable market in the United States for the Galt VTI is estimated to be approximately $14 million of annual sales and growing at 5 percent annually. The Galt VTI is expected to launch in the second half of 2012, with revenue in the range of $300,000 expected based on indications of interest from Galt Medical’s customer base. Within 12 months of launch, the company expects the Galt VTI to generate annualized revenue of $1 million to $2 million, with gross profit margins higher than currently being realized in Galt Medical’s surgical products segment.

“Both current and potential new customers have expressed significant interest in the Galt VTI product,” said M. Christine Jacobs, chairwoman and CEO of Theragenics Corp. “We expect this product to be a valuable addition to our current vascular access product platform, offering important new features along with the same high quality to which our customers are accustomed.

“The Galt VTI product is the most significant internally developed product released by our surgical products segment to date. We intend to continue to focus on the development of new products that can utilize the FDA 510(k) clearance process in all our business units,” added Jacobs.

Galt Medical is a wholly-owned subsidiary of Theragenics. The Galt business unit manufactures and distributes vascular access products, including introducers and guidewires used in interventional radiology, interventional cardiology and vascular surgery. Theragenics operates two business segments: its surgical products business and its brachytherapy seed business.

For more information: www.theragenics.com

Related Content

Merit Medical Announces Advanced Interventional Cardiology Transradial Intervention Education Course
News | Radial Access| August 23, 2017
Merit Medical Systems Inc. will partner with internationally renowned interventional cardiologist Ferdinand Kiemeneij,...
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Cardiac Imaging| August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Virtual Phantoms Inc. Releases VirtualDose-IR
Technology | Radiation Dose Management| August 07, 2017
Virtual Phantoms Inc. announced the release of VirtualDoseIR, a tool for assessing organ dose from interventional...
Moffitt Cancer Center Enhances Patient Care with Toshiba Medical's Infinix-i 4-D
News | Interventional Radiology| August 03, 2017
Cancer patients at Moffitt Cancer Center in Tampa, Fla., now have access to advanced diagnostic imaging for fast and...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Sponsored Content | Videos | Peripheral Artery Disease (PAD)| July 25, 2017
This video case study, provided by Gore Medical, is titled "Tackling Complex Cases in Dialysis Access," by John Ross,
ACCESS PTS Study Demonstrates Efficacy of EKOS Therapy for Post-Thrombotic Syndrome
News | Deep Vein Thrombosis| July 07, 2017
BTG plc recently highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th...
Siemens Healthineers Announces First U.S. Install of Artis Pheno Angiography System
News | Angiography| July 05, 2017
Michigan Medicine recently became the first healthcare institution in the United States to install the Artis pheno, the...
Sponsored Content | Videos | Venous Therapies| June 27, 2017
This video, provided by Ekos, demonstrates the EkoSonic endovascular System thrombolytic system to treat deep vein th
Infab Introduces Revolution Lead Aprons
Technology | Radiation Dose Management| June 01, 2017
June 1, 2017 — Infab Corp.
Overlay Init